US Bancorp DE Cuts Stock Position in Repligen Co. (NASDAQ:RGEN)

US Bancorp DE decreased its holdings in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 34.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,032 shares of the biotechnology company's stock after selling 5,261 shares during the quarter. US Bancorp DE's holdings in Repligen were worth $1,493,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of RGEN. Vanguard Group Inc. boosted its holdings in shares of Repligen by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 5,100,013 shares of the biotechnology company's stock worth $937,994,000 after purchasing an additional 21,719 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Repligen by 21.0% in the second quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company's stock worth $172,749,000 after buying an additional 237,884 shares in the last quarter. Conestoga Capital Advisors LLC grew its position in Repligen by 26.7% during the second quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company's stock valued at $119,363,000 after acquiring an additional 199,322 shares during the last quarter. Thrivent Financial for Lutherans raised its stake in shares of Repligen by 240.5% during the second quarter. Thrivent Financial for Lutherans now owns 601,829 shares of the biotechnology company's stock worth $75,866,000 after acquiring an additional 425,061 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Repligen by 39.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 429,524 shares of the biotechnology company's stock worth $54,149,000 after acquiring an additional 121,305 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

Insider Transactions at Repligen

In related news, Director Anthony Hunt sold 22,191 shares of the company's stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the sale, the director now directly owns 139,840 shares of the company's stock, valued at $20,328,540.80. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 1.20% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Royal Bank of Canada reaffirmed an "outperform" rating and set a $205.00 target price on shares of Repligen in a report on Thursday, September 26th. JPMorgan Chase & Co. boosted their target price on Repligen from $190.00 to $200.00 and gave the company an "overweight" rating in a research note on Wednesday, July 31st. Wells Fargo & Company started coverage on Repligen in a research report on Tuesday, August 27th. They set an "overweight" rating and a $180.00 price target on the stock. UBS Group lowered their price objective on Repligen from $205.00 to $185.00 and set a "buy" rating for the company in a research report on Wednesday, July 31st. Finally, Benchmark restated a "hold" rating on shares of Repligen in a report on Monday, August 5th. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $190.25.

Repligen Trading Down 2.2 %

NASDAQ RGEN traded down $3.18 during trading on Friday, hitting $140.70. The company had a trading volume of 543,898 shares, compared to its average volume of 654,429. The company's fifty day moving average is $141.56 and its 200-day moving average is $145.39. Repligen Co. has a one year low of $113.50 and a one year high of $211.13. The company has a current ratio of 6.65, a quick ratio of 5.56 and a debt-to-equity ratio of 0.26. The company has a market cap of $7.88 billion, a price-to-earnings ratio of -3,517.50, a price-to-earnings-growth ratio of 4.19 and a beta of 0.96.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.